HNB
AMRX icon

Huntington National Bank’s Amneal Pharmaceuticals AMRX Stock Holding History

Huntington National Bank’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208 Buy
+12
New +$164 ﹤0.01% 2703

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Huntington National Bank's AMRX Position: Q2 2026 in Review

Huntington National Bank opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 12 shares worth $208. The stake represents ﹤0.01% of the portfolio and ranks #2703 among its holdings.

231 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Huntington National Bank held 12 shares of Amneal Pharmaceuticals worth $208 as of Q2 2026.
  • Amneal Pharmaceuticals was a new Huntington National Bank position in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2703 holding.
  • 231 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.